1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Alexza partners with Teva for US Adasuve launch

 
• By Mandy Jackson

Alexza Pharmaceuticals will receive $40 million up front under a license and supply agreement with Teva Pharmaceuticals USA to commercialize Adasuve (loxapine) inhalation powder.

Alexza Pharmaceuticals will receive $40 million up front under a license and supply agreement with Teva Pharmaceuticals USA to commercialize Adasuve (loxapine) inhalation powder.

The deal was announced nearly five months after US FDA approval for the drug, which is administered by Alexza's Staccato device to treat agitation in adults with bipolar I disorder...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Lilly To Diversify Pain Pipeline With SiteOne Acquisition

 
• By Joseph Haas

Deal snapshot: With several internal non-opioid pain candidates in Phase II or earlier, Lilly looks to add R&D potential in pain with $1bn buyout of SiteOne.

Angelini Advances Brain Health Ambitions With GRIN Pact

 
• By Kevin Grogan

The Italian drugmaker gets rights to Phase III-ready asset radiprodil.

Sanofi Makes Alzheimer’s Bet With Vigil Buy

 
• By Kevin Grogan

The French drugmaker is expanding its neurology activities with the $470m deal.

In Brief: US FDA Delay Sends Biohaven Shares Down

 
• By Andrew McConaghie

The US regulator’s decision has taken Biohaven and investors by surprise, with the reason for a ‘major amendment’ status not clear.

More from Therapeutic Category